VeriSilicon Unveils Next-Generation High-Performance Vitality Architecture GPU IP Series
VeriSilicon (688521.SH) today announced the launch of its latest Vitality architecture Graphics Processing Unit (GPU) IP series, designed to deliver high-performance computing across a wide range of applications, including cloud gaming, AI PC, and both discrete and integrated graphics cards.
VeriSilicon’s new generation Vitality GPU architecture delivers exceptional advancements in computational performance with scalability. It incorporates advanced features such as a configurable Tensor Core AI accelerator and a 32MB to 64MB Level 3 (L3) cache, offering both powerful processing power and superior energy efficiency. Additionally, the Vitality architecture supports up to 128 channels of cloud gaming per core, addressing the needs of high concurrency and high image quality cloud-based entertainment, while enabling large-scale desktop gaming and applications on Windows systems. With robust support for Microsoft DirectX 12 APIs and AI acceleration libraries, this architecture is ideally suited for a wide range of performance-intensive applications and complex computing workloads.
With over 20 years of development, VeriSilicon’s GPU IP has a proven track record in diverse segments, from low-power IoT Microcontroller Units (MCUs) to high-performance processors for automotive and computing applications. To date, over 2 billion chips featuring VeriSilicon’s GPU IP have been shipped globally.
“Parallel computing demand has been steadily increasing over the last decade, with a dramatic surge driven by the rise of AI computing. GPUs have become essential processors in this new era, expanding their role beyond traditional applications like gaming,” said Weijin Dai, Chief Strategy Officer, Executive Vice President and General Manager of IP Division at VeriSilicon. “The Vitality architecture GPU represents the next generation of high-performance and energy-efficient GPU. With over 20 years of GPU development experience across diverse market segments, the Vitality architecture is built to support the most advanced GPU APIs. Its scalability enables widespread deployment in fields such as automotive systems and mobile computing devices. We are thrilled to collaborate with leading customers to integrate this groundbreaking technology into their products, addressing the growing demand for GPUs and advanced computing solutions.”
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217414024/en/
Contacts
Media Contact: press@verisilicon.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MBK Partners and Young Poong Expand Stake in Korea Zinc to 46.7% of Voting Shares19.12.2024 06:59:00 CET | Press Release
MBK Partners, through its special-purpose company, Korea Corporate Investment Holdings Co., Ltd., has acquired an additional 1.13% stake in Korea Zinc. This latest acquisition increases MBK Partners and Young Poong’s combined stake in Korea Zinc to 40.97% of the total issued shares and 46.7% of the voting shares, excluding treasury stock, positioning the group closer to majority control. According to disclosures from the Financial Supervisory Service’s electronic reporting system, Korea Corporate Investment Holdings purchased 234,451 shares (1.13% of Korea Zinc’s total issued shares) through open-market trading under the "Careful Discretion" (CD) method between November 12 and December 18. With this transaction, Korea Corporate Investment Holdings now independently holds 7.82% of Korea Zinc's total issued shares (8.9% of voting shares). This includes the 5.32% stake acquired via a tender offer completed on October 14 and a 1.36% stake purchased on the open market last month. Combined w
Brightcove Drives Global Customer Growth and Value Through Strategic Partnerships with Leading MarTech Solutions18.12.2024 17:09:00 CET | Press Release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, is sharing significant enhancements to its platform through strategic partnerships to enhance the video content creation, distribution and monetization process. As part of the goal to help customers build more cohesive, easy-to-deploy martech stacks, Brightcove has integrated capabilities from companies like Acquia that deliver additional benefits to customers. “As we build strategic partnerships with key providers, we continually look at ways to help our customers reach their business goals. With the right partners, we enable marketers to fully leverage their content and get the most value out of it,” said David Beck, Chief Operating Officer at Brightcove. “Integrating our partners’ strengths – like Acquia’s DAM capabilities – seamlessly into Brightcove’s platform makes it easier for our customers to capture, deploy, and measure video to deliver compelling content that drives engagement and business with
GC Aesthetics® Announces Decade-Long Clinical Evaluation of PERLE™ Breast Implants18.12.2024 16:56:00 CET | Press Release
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce the initiation of a significant multi-center and prospective clinical study in Europe to evaluate, and confirm, the safety, effectiveness, and patient satisfaction associated with the innovative PERLE™ smooth opaque round breast implant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218630395/en/ GC Aesthetics' PERLE™ Breast Implant features a proprietary surface technology (BioQ™) and GCA’s industry-leading gel technology (Emunomic™ Breast Tissue Dynamic Gel). (Photo: Business Wire) This extensive study brings together leading surgeons from the NHS and private clinics in the UK, as well as from private practices across Europe, ensuring a robust and diverse dataset that addresses both cosmetic and reconstructive indications. “By generating high-quality clin
Andersen Global Expands Capabilities with Addition of Valora18.12.2024 15:30:00 CET | Press Release
Andersen Global continues to broaden its service offerings through a Collaboration Agreement with Valora, an independent firm specializing in providing custom solutions for both private and institutional clients globally. Valora operates with offices in Miami and Raleigh, along with a global presence in the Dominican Republic, U.K., and Cayman Islands. Founded in 2011 by Partner Luis de Leon, Valora offers a comprehensive range of services, including valuation, performance, accounting and administration, global entity management, fund services, and other tailored solutions. “Collaborating with Andersen is an excellent fit for both our clients and our team,” said Luis. “The synergies within our service offerings will enable us to deliver comprehensive, integrated solutions with ever-increasing global reach.” Global Chairman and CEO of Andersen Mark L. Vorsatz stated, “Valora’s team and culture, along with their practice focus, are well aligned with our organization as we continue to exp
Novotech Publishes Report on the Global COVID-19 Clinical Trial Landscape, Highlighting Key Trends, Therapeutic Advancements, and Challenges in Drug Development18.12.2024 14:05:00 CET | Press Release
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics, has released an in-depth report "COVID-19: Global Clinical Trial Landscape 2024." This report delivers a robust analysis of ongoing and completed COVID-19 clinical trials, therapeutic strategies, and funding trends, offering essential insights for researchers and biotech leaders in the evolving COVID-19 research landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218899045/en/ The COVID-19 pandemic has led to significant advancements in clinical research and therapeutic innovation. Novotech’s report offers an authoritative analysis of global trial distribution, patient recruitment trends, and emerging therapeutic strategies, drawing on over 5,000 clinical trials conducted since 2019 across Asia-Pacific, North America, Europe, and beyond
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom